We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Elekta (EKTA-B.ST) announced today that its latest solution for proton therapy, Monaco®* treatment planning for protons, has received 510(k) clearance from the U.S. Food and Drug Administration.
Concord Medical Services Holdings Limited is pleased to announce that on June 29, 2017 its subsidiary, Guangzhou Concord Cancer Hospital Ltd., entered into an agreement with Varian Medical Systems Particle Therapy